ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal
This article was originally published in PharmAsia News
Executive Summary
ArQule's agreement with Tokyo biotech Kyowa to develop and commercialize Phase I oncology molecule ARQ 197 in Asia will give the firm a much-needed cash infusion to support the product's development in the U.S
You may also be interested in...
ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi Sankyo
ArQule signed a two-part deal with Daiichi Sankyo Nov. 10 that gives the biotech important non-dilutive funding as well as validation for its discovery platform. In exchange for broad commercialization rights to ArQule's lead compound, the Phase II oncologic ARQ 197, Daiichi will pay $75 million in upfront funding along with up to $560 million in potential milestones
ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi Sankyo
ArQule signed a two-part deal with Daiichi Sankyo Nov. 10 that gives the biotech important non-dilutive funding as well as validation for its discovery platform. In exchange for broad commercialization rights to ArQule's lead compound, the Phase II oncologic ARQ 197, Daiichi will pay $75 million in upfront funding along with up to $560 million in potential milestones
Kyowa Hakko’s Parkinson’s Drug Is Not Approvable – U.S. FDA
Kyowa Hakko will work with U.S. FDA to determine a path forward for its Parkinson's treatment istradefylline (KW-6002) after receiving a "not approvable" letter from the agency Feb. 25, the Tokyo-based firm said Feb. 27